Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4105-4111

  De Wit, Ronald ^a   Herrstedt, J ^a   Rapoport, B ^a   Carides, A D ^a   Carides, G ^a   Elmer, M ^a   Schmidt, C ^a   Evans, J K ^a   Horgan, K J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CISPLATIN; DEXAMETHASONE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR;

ADD ON THERAPY; ADULT; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; AGED; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; RECEPTORS, NEUROKININ-1; TREATMENT OUTCOME; VOMITING;

EID: 0346556083     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.128     Document Type: Article

References (16)

1. Griffin AM, Butow PN, Coates AS, et al: On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189-195, 1996
2. 3 antagonists. Br J Cancer 76:1055-1061, 1997
3. 3 receptor antagonists. Support Care Cancer 2:286-292, 1994
4. Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971-2994, 1999
5. Tuvorath R, Hesketh PJ: Drug treatment of chemotherapy-induced delayed emesis. Drugs 52:639-648, 1996
6. 3 antagonist prophylaxis is not maintained. J Clin Oncol 14:644-651, 1996
7. de Wit R, van den Berg H, Burghouts J, et al: Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 77:1487-1491, 1998
8. Sigsgaard T, Herrstedt J, Handberg J, et al: Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 19:2091-2097, 2001
9. Campos D, Pereira JR, Reinhardt RR, et al: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767, 2001
10. Navari R, Reinhardt R, Gralla RJ, et al: Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med 340:190-195, 1999
11. Hesketh PJ, Kris MG, Grunberg SM, et al: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997
12. 1 antagonist aprepitant for chemotherapy-induced nausea and vomiting. Cancer 97:2290-2300, 2003
13. 3 antiemetics. Support Care Cancer 6:244-247, 1998
14. Poli-Bigelli S, Rodrigues-Pereira J, Carides A, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting. Results from a randomized, double-blind, placebo controlled trial in Latin America. Cancer 97:3090-3098, 2003
15. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurakinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-The Aprepitant Protocol 052 Study Group. J Clin Oncol: 21:4112-4119, 2003
16. Hesketh PJ, Van Belle S, Aapro M, et al: Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39: 1074-1080, 2003